Type 2 diabetes mellitus (T2DM) and metabolic syndrome contribute to hypertriglyceridemia, which may increase residual risk of cardiovascular disease in patients with elevated triglyceride (TG) levels despite optimal low-density lipoprotein cholesterol (LDL-C) levels with statin therapy. One night she might go to bed at 11 pm and the next night she might stay up on the computer until 4 am. Diabetes medications were the only nonspecialty therapy class to have a significant increase in PMPY drug spend in 2014, largely due to two newly approved medications known as sodium-glucose co-transporter 2 (SGLT2) inhibitors. We also evaluated predictors of cost differences using multivariate regression models. For diabetes agents, the median cost per patient was $158.34 and varied from $123.34 in the least expensive quartile to $198.31 in the most expensive quartile (P < .001). Diabetic prescription utilization and medication adherence increased by approximately 3.0% in year 1 and dropped in year 2. Qualification for the LTI card does not depend on a person’s income, but on being on a list of designated illnesses that qualify for the card, of which diabetes is one. "Instead of paying for expensive treatment on the back end, [this] puts the doctor or the prescriber in the position of being able to come up with the same diagnosis, tell the patient they need to significantly increase their intake of fruits and vegetables...and then can give them a prescription that actually allows them to afford to purchase the foods they need," says Michel Nischan, founder and CEO of Wholesome Wave, the organization that pioneered FVRx programs. The greatest relative increase occurred in the prescription of thiazolidinediones. I understand that Pharmacy2U will receive my registration details from DCUK for the purpose of providing the Prescription Service and that no medical or medication data is shared. A meta-analysis in non-diabetic and diabetic patients suggested that diabetic patients, after adjustment for baseline characteristics, benefit even more than non-diabetes patients from lipid-lowering therapy in both primary and secondary prevention . For those without an endo or who aren't frequent visitors of their regular docs, and especially for those people without insurance coverage, this expanded availability of a life-sustaining medication would be a very welcome change. Finally, the “ease” of implementing a pharmacy benefit change is also appealing to an employer.